Kate Bingham
Managing Partner
SV Health Investors
Kate Bingham has spent over 30 years in building and investing in biotech companies, where she is a Managing Partner at SV Health Investors. SV’s investments have resulted in the launch of 24 new drugs for the treatment of patients with inflammatory and autoimmune disease and cancer. She played an active role in setting up SV’s Dementia Discovery Funds.
In May 2020 Kate was appointed Chair of the UK Vaccine Taskforce, reporting to the Prime Minster to lead UK efforts to find and manufacture a COVID-19 vaccine. It was a six month engagement and she stepped down as Chair in December. On December 8th 2020 the UK started COVID-19 vaccinations – the first Western country to do so.
She serves on the Board of the Francis Crick Institute and ARIA.
